Stocks Overview

LAST PRICE
0.6116
TODAY'S CHANGE (%)
Trending Up0.0363 (6.3098%)

Bid / Lots
0.6000/ 65
Ask / Lots
0.6200/ 6
Open / Previous Close
0.5614 / 0.5753
Day Range
Low 0.5528
High 0.6216
52 Week Range
Low 0.5528
High 2.5300
Volume
582,908
above average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TSX Comp
TSX Venture
DJIA
S&P 500
NASDAQ

Price Comparison Graph. See accessible table below

1 Day Comparison Chart Accessibility Table. Thursday's close: 0.5755
Time	Volume	BLRX
09:32 ET	62786	0.5588
09:34 ET	1703	0.5654
09:36 ET	1398	0.5657
09:38 ET	796	0.5605
09:39 ET	2400	0.5612
09:43 ET	3361	0.5698
09:45 ET	13965	0.56
09:48 ET	6252	0.5528
09:50 ET	2936	0.5566
09:52 ET	13211	0.5548
09:54 ET	100	0.5604
09:56 ET	11832	0.5692
09:59 ET	1558	0.5715
10:01 ET	5200	0.575
10:03 ET	7440	0.55615
10:06 ET	500	0.56635
10:10 ET	150	0.56725
10:17 ET	2500	0.5633
10:19 ET	816	0.5674
10:24 ET	7941	0.5616
10:26 ET	56140	0.5658
10:28 ET	10287	0.56085
10:30 ET	3240	0.5762
10:32 ET	3100	0.5762
10:33 ET	4496	0.5674
10:35 ET	2431	0.5675
10:39 ET	538	0.5676
10:42 ET	1661	0.5684
10:48 ET	1400	0.5684
10:50 ET	5055	0.5689
10:51 ET	250	0.5689
10:57 ET	850	0.5744
11:00 ET	600	0.571699
11:02 ET	433	0.57
11:04 ET	1041	0.5703
11:09 ET	403	0.5744
11:11 ET	688	0.57
11:13 ET	100	0.5702
11:26 ET	150	0.5743
11:29 ET	835	0.5701
11:31 ET	300	0.57225
11:33 ET	8744	0.57
11:36 ET	4779	0.5701
11:38 ET	4880	0.5708
11:40 ET	1186	0.5706
11:42 ET	500	0.5708
11:44 ET	1338	0.5713
11:45 ET	1500	0.571
11:54 ET	6990	0.5706
11:56 ET	6352	0.5706
11:58 ET	5700	0.5706
12:03 ET	500	0.58
12:05 ET	157	0.5799
12:07 ET	4678	0.5751
12:09 ET	3210	0.5702
12:16 ET	100	0.5786
12:18 ET	3083	0.5758
12:20 ET	993	0.57825
12:21 ET	1565	0.5884
12:23 ET	6420	0.5852
12:25 ET	5528	0.5832
12:27 ET	7393	0.57895
12:32 ET	14413	0.5805
12:34 ET	2183	0.575
12:48 ET	707	0.581
12:52 ET	300	0.584751
12:54 ET	7134	0.58025
12:56 ET	1800	0.5888
12:59 ET	1500	0.5858
01:01 ET	1974	0.5807
01:03 ET	827	0.581
01:17 ET	4571	0.5808
01:19 ET	6763	0.5853
01:21 ET	200	0.5892
01:24 ET	1719	0.589
01:26 ET	2654	0.589
01:28 ET	2187	0.589
01:42 ET	600	0.5891
01:44 ET	4200	0.589086
01:46 ET	4594	0.589
01:48 ET	1409	0.589
01:50 ET	3545	0.589
01:51 ET	1587	0.589
01:53 ET	5879	0.589
01:55 ET	4522	0.589
01:57 ET	5021	0.5897
02:02 ET	1500	0.5894
02:06 ET	22663	0.589
02:08 ET	5400	0.589
02:09 ET	4721	0.5891
02:11 ET	3000	0.5891
02:13 ET	6083	0.589
02:15 ET	2200	0.5891
02:18 ET	1700	0.589099
02:20 ET	6700	0.5966
02:22 ET	3000	0.5984
02:24 ET	9950	0.599999
02:26 ET	3308	0.6
02:27 ET	3300	0.6183
02:29 ET	3200	0.6172
02:31 ET	5158	0.62
02:38 ET	7107	0.6208
02:40 ET	15500	0.62
02:42 ET	1700	0.6212
02:44 ET	200	0.6212
02:47 ET	182	0.62111
02:49 ET	10300	0.6216
02:54 ET	2308	0.6215
03:00 ET	4600	0.6203
03:02 ET	6470	0.6166
03:03 ET	1287	0.6113
03:05 ET	100	0.6163
03:09 ET	102	0.611
03:20 ET	1200	0.611
03:27 ET	346	0.611
03:39 ET	496	0.6129
03:41 ET	1000	0.6119
03:43 ET	8327	0.6153
03:45 ET	4660	0.61
03:48 ET	1400	0.6156
03:52 ET	5000	0.6115
03:54 ET	2490	0.6156
03:56 ET	162	0.612
03:57 ET	2177	0.6206
03:59 ET	4781	0.6116

Data delayed at least 15 minutes.

Apr 17, 2024
- DJ BioLine RX Price Target Maintained With a $21.00/Share by HC Wainwright & Co., from 1:44PM ET on Wednesday Apr 17, 2024 by Dow Jones
  1:44PM ET on Wednesday Apr 17, 2024 by Dow Jones
- BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA(R) (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting, from 7:00AM ET on Wednesday Apr 17, 2024 by Dow Jones
  7:00AM ET on Wednesday Apr 17, 2024 by Dow Jones
Apr 10, 2024
- BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement, from 7:00AM ET on Wednesday Apr 10, 2024 by Dow Jones
  7:00AM ET on Wednesday Apr 10, 2024 by Dow Jones
- Press Release: BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement, from 7:00AM ET on Wednesday Apr 10, 2024 by Dow Jones
  7:00AM ET on Wednesday Apr 10, 2024 by Dow Jones
Apr 1, 2024
- BioLineRx Announces $6 Million Registered Direct Offering, from 9:00AM ET on Monday Apr 01, 2024 by Dow Jones
  9:00AM ET on Monday Apr 01, 2024 by Dow Jones

0 New Today

Industry Peers Overview Table
Company sortable	Market Cap sortable	P/E Ratio (TTM) sortable	EPS Growth (5yr) sortable
United StatesBLRX BioLine RX Ltd	53.0M	-0.6x	---
United StatesHCWB HCW Biologics Inc	52.9M	-2.0x	---
United StatesKRON Kronos Bio Inc	60.1M	-0.5x	---
United StatesCUE Cue Biopharma Inc	66.4M	-1.2x	---
United StatesKZR Kezar Life Sciences Inc	58.6M	-0.6x	---
United StatesDYAI Dyadic International Inc	43.2M	-6.3x	---
As of 2024-04-27

BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.

Contact Information

Headquarters: Modi'in Technology Park 2 HaMa'ayan StreetMODIIN, Israel 7177871
Phone: ---
Fax: ---

Executives

Chairman of the Board: Aharon Schwartz
Chief Executive Officer: Philip Serlin
Chief Financial Officer: Mali Zeevi
Vice President - Development: Ella Sorani
Vice President-Clinical & Medical Affairs: Abi Vainstein-Haras

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Skip section

INK Company InsiderDetailed daily analysis of insider activity and holdings for stocks and income trusts listed in Canada, based on filings from SEDI®.

Fundamentals Table
Market Cap	$53.0M
Revenue (TTM)	$4.8M
Shares Outstanding	79.9M
Dividend Yield	0.00%
Annual Dividend Rate	---
Ex-Dividend Date	01-01-01
Pay Date	01-01-01
Beta	1.49
EPS	$-0.95
Book Value	$0.18
P/E Ratio	-0.6x
Price/Sales (TTM)	11.0
Price/Cash Flow (TTM)	---
Operating Margin	-1,035.29%

*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.

BioLine RX Ltd
NASDAQ:BLRXUnited States

Search Criteria

Charts

Recent News

Apr 17, 2024

DJ BioLine RX Price Target Maintained With a $21.00/Share by HC Wainwright & Co., from 1:44PM ET on Wednesday Apr 17, 2024 by Dow Jones

BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA(R) (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting, from 7:00AM ET on Wednesday Apr 17, 2024 by Dow Jones

Apr 10, 2024

BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement, from 7:00AM ET on Wednesday Apr 10, 2024 by Dow Jones

Press Release: BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement, from 7:00AM ET on Wednesday Apr 10, 2024 by Dow Jones

Apr 1, 2024

BioLineRx Announces $6 Million Registered Direct Offering, from 9:00AM ET on Monday Apr 01, 2024 by Dow Jones

Biotechnology Industry Peers

Company Information

Contact Information

Executives

Ratings

Reports

Fundamentals

Calendar